Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- ATNM-400'S TARGET ANTIGEN IS OVEREXPRESSED IN BREAST CANCER AND ITS EXPRESSION IS FURTHER INCREASED IN BREAST CANCER CELLS RESISTANT TO STANDARD OF CARE ENDOCRINE THERAPY, TAMOXIFEN AND THE HER2 THERAPY TRASTUZUMAB - THE ACTINIUM-225 ALPHA-EMITTER PAYLOAD OF ATNM-400 INDUCED IRREVERSIBLE DOUBLE-STRAND DNA BREAKS AND HAS THE POTENTIAL TO PRODUCE POTENT LOCALIZED TUMOR KILLING WITH REDUCED OFF-TARGET LUNG TOXICITY THAT LIMITS THE USE OF ANTIBODY DRUG CONJUGATES - DATA SUPPORTS THE CONTINUED DEVELOPMENT OF ATNM-400 AS A MONOTHERAPY OR COMBINATION THERAPY TO ADDRESS MULTIPLE BREAST CANCER SUBTYPES WITH LIMITED TREATMENT OPTIONS NEW YORK , DEC. 12, 2025 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM), A LEADER IN THE DEVELOPMENT OF DIFFERENTIATED TARGETED RADIOTHERAPIES,TODAY ANNOUNCED THE PRESENTATION OF NEW PRECLINICAL DATA FOR ATNM-400, ITS FIRST-IN-CLASS ACTINIUM-225 (AC-225) BASED ANTIBODY RADIOCONJUGATE, AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS). THE DATA HIGHLIGHT ROBUST ANTI-TUMOR ACTIVITY AND A FAVORABLE TOLERABILITY PROFILE ACROSS A BROAD PANEL OF PRECLINICAL BREAST CANCER MODELS, INCLUDING HORMONE RECEPTORPOSITIVE (HR+), TRIPLE-NEGATIVE BREAST CANCER (TNBC), AND TAMOXIFEN- AND TRASTUZUMAB-RESISTANT TUMORS.

ACTINIUM PHARMACEUTICALS PRESENTS NEW PRECLINICAL DATA DEMONSTRATING POTENT ANTI-TUMOR ACTIVITY OF ATNM-400 ACROSS MULTIPLE BREAST CANCER SUBTYPES INCLUDING HORMONE RECEPTOR-POSITIVE, TRIPLE-NEGATIVE, AND TAMOXIFEN- AND HER2 THERAPY-RESISTANT BREAST CANCER MODELS AT SABCS 2025

PRESENTATION TO INCLUDE NEW DATA IN TRIPLE-NEGATIVE DISEASE, A BREAST CANCER SUBTYPE WITH POOR OUTCOMES AND LIMITED VIABLE TREATMENT OPTIONS ATNM-400 OVERCOMES HER2 THERAPY RESISTANCE AND REPRESENTS A NOVEL TARGETED RADIOTHERAPY WITH THE POTENTIAL TO AVOID OFF-TARGET TOXICITIES INCLUDING ILD THAT CONSTRAINS OTHER THERAPEUTIC MODALITIES SUCH AS ANTIBODY DRUG CONJUGATES ATNM-400 HAS DEMONSTRATED THE POTENTIAL TO OVERCOME RESISTANCE TO FIRST-LINE TAMOXIFEN ENDOCRINE THERAPY DATA TO BE PRESENTED ON DECEMBER 11, 2025 AT 5:00 PM CT NEW YORK , DEC. 1, 2025 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM), A LEADER IN THE DEVELOPMENT OF DIFFERENTIATED TARGETED RADIOTHERAPIES, TODAY ANNOUNCED COMPELLING PRECLINICAL DATA FOR ATNM-400, A FIRST-IN-CLASS ACTINIUM-225 (AC-225) ANTIBODY RADIOCONJUGATE, IN HORMONE RECEPTOR POSITIVE (HR+), HER2 POSITIVE (HER2+) AND TRIPLE-NEGATIVE BREAST CANCER (TNBC) THAT WILL BE PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) BEING HELD DECEMBER1014, 2025 IN SANANTONIO, TEXAS. THE DATA DEMONSTRATES SIGNIFICANT ANTI-TUMOR ACTIVITY IN BREAST CANCER MODELS RESISTANT TO STANDARD-OF-CARE THERAPIES INCLUDING ENDOCRINE THERAPY TAMOXIFEN AND HER2-TARGETED THERAPY TRASTUZUMAB (HERCEPTIN, ROCHE) AS WELL AS POTENT TUMOR GROWTH INHIBITION IN TNBC MODELS.

ACTINIUM PHARMACEUTICALS ANNOUNCES ATNM-400 DATA DEMONSTRATING POTENT EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER AND ABILITY TO OVERCOME ENDOCRINE AND HER2-TARGETED THERAPY RESISTANCE BEING PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM

VANCOUVER, KELOWNA, AND DELTA, BRITISH COLUMBIA--(NEWSFILE CORP. - NOVEMBER 17, 2025) - INVESTORIDEAS.COM, A GO-TO INVESTING PLATFORM COVERING BIOTECH AND PHARMA STOCKS ISSUES A SNAPSHOT LOOKING AT THE RADIOTHERAPY CANCER MARKET, FEATURING ACTINIUM PHARMACEUTICALS, INC. (NYSE AMERICAN: ATNM), A PIONEER IN THE DEVELOPMENT OF DIFFERENTIATED, TARGETED RADIOTHERAPIES INTENDED TO MEANINGFULLY IMPROVE OUTCOMES FOR PATIENTS WITH ADVANCED CANCERS. ACTINIUM IS DEPLOYING ITS TECHNOLOGIES, CAPABILITIES AND INTELLECTUAL PROPERTY WITH APPROXIMATELY 250 ISSUED AND PENDING PATENTS WORLDWIDE, TO DEVELOP NEXT-GENERATION RADIOTHERAPIES FOCUSED ON SOLID TUMORS, HEMATOLOGY AND CONDITIONING FOR CELLULAR THERAPIES.

THE RACE FOR THE GLOBAL RADIOTHERAPY CANCER MARKET; ACTINIUM PHARMACEUTICALS' (ATNM) BIG BET

- ATNM-400 EXHIBITS SUPERIOR EFFICACY WITH 3-5X GREATER TUMOR GROWTH INHIBITION COMPARED TO FRONT LINE THERAPY OSIMERTINIB (EGFR TKI TAGRISSO), SECOND LINE THERAPY DATO-DXD (TROP-2 ADC DATROWAY) AND THIRD LINE THERAPY AMIVANTAMAB (EGFR-CMET BISPECIFIC RYBREVANT) - COMBINATION OF ATNM-400 AND OSIMERTINIB RESULTED IN COMPLETE TUMOR REGRESSION IN 100% OF TUMOR BEARING ANIMALS; SYNERGISTIC MECHANISM SUPPORTED BY INCREASED ATNM-400 TARGET ANTIGEN EXPRESSION AFTER EGFR INHIBITION WITH OSIMERTINIB - IMPROVED PROGRESSION FREE SURVIVAL HAS BEEN DEMONSTRATED CLINICALLY WITH THE COMBINATION OF OSIMERTINIB AND EXTERNAL BEAM RADIOTHERAPY PROVIDING STRONG RATIONALE FOR A COMBINATION WITH TARGETED ALPHA-THERAPY - DATA VALIDATES THE MULTI-TUMOR POTENTIAL OF ATNM-400 IN MULTIPLE DISEASE AND TREATMENT SETTINGS THAT SUPPORT SEVERAL BLOCKBUSTER DRUGS NEW YORK , OCT. 27, 2025 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC.(NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF DIFFERENTIATED TARGETED RADIOTHERAPIES, TODAY ANNOUNCED THE PRESENTATION OF THE FIRST EVER PRECLINICAL DATA OF ATNM-400 IN NON-SMALL CELL LUNG CANCER (NSCLC). ATNM-400 A NOVEL, MULTI-INDICATION FIRST-IN-CLASS ANTIBODY RADIOCONJUGATE ARMED WITH THE POTENT ALPHA-EMITTER ACTINIUM-225 (AC-225) IS ACTINIUM'S LEAD SOLID TUMOR PROGRAM, WHICH IS ALSO BEING STUDIED IN PROSTATE CANCER.

ACTINIUM ANNOUNCES SUPERIOR ANTI-TUMOR ACTIVITY OF ATNM-400 IN LUNG CANCER COMPARED TO THE LEADING FIRST, SECOND AND THIRD-LINE APPROVED EGFR MUTANT THERAPIES AND MECHANISTIC SYNERGY WITH OSIMERTINIB AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

- ATNM-400 TARGETS A NOVEL,NON-PSMA ANTIGEN IMPLICATED IN DISEASE BIOLOGY WITHCONTINUED EXPRESSION FOLLOWING ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY AND 177LU-PSMA-617 THERAPY, ENABLING POTENT ACTIVITY INDEPENDENT OF PSMA EXPRESSION - ATNM-400 DEMONSTRATED SUPERIOR EFFICACY OVERPSMA-TARGETED RADIOLIGAND THERAPY(177LU-PSMA-617 AND 225AC-PSMA-617) WITH ENHANCED TUMOR CONTROL AND PROLONGED SURVIVAL IN LOW-PSMA AND TREATMENT-RESISTANT MODELS - DEMONSTRATED DURABLE ANTI-TUMOR RESPONSES, EXCEEDING THOSE ACHIEVED WITH THEARPI ENZALUTAMIDE - COMBINATION OF ATNM-400 WITHENZALUTAMIDE ACHIEVED COMPLETE TUMOR REGRESSIONIN 40% OF PROSTATE CANCER-BEARING ANIMALS, DEMONSTRATING STRONG MECHANISTIC SYNERGY WITH AR PATHWAY INHIBITION NEW YORK , OCT. 24, 2025 /PRNEWSWIRE/ -- ACTINIUM PHARMACEUTICALS, INC.(NYSE AMERICAN: ATNM) (ACTINIUM OR THE COMPANY), A PIONEER IN THE DEVELOPMENT OF DIFFERENTIATED TARGETED RADIOTHERAPIES, TODAY HIGHLIGHTED NEW PRECLINICAL DATA FOR ATNM-400, ITS NOVEL, FIRST-IN-CLASS ANTIBODY RADIOCONJUGATE ARMED WITH THE POTENT ALPHA-EMITTER ACTINIUM-225 (AC-225) AT THE 32ND ANNUAL PROSTATE CANCER FOUNDATION (PCF) SCIENTIFIC RETREAT BEING HELD OCTOBER 23  25, 2025 IN CARLSBAD, CA. ATNM-400, WHICH TARGETS A NON-PSMA ANTIGEN ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND TREATMENT RESISTANCE, DEMONSTRATED SUPERIOR TUMOR CONTROL AND IMPROVED OVERALL SURVIVAL COMPARED WITH THE ACTIVE AGENTS IN KEY STANDARD-OF-CARE THERAPIES INCLUDING ENZALUTAMIDE (THE ACTIVE AGENT IN XTANDI, ASTELLAS/PFIZER) AND 177LU-PSMA-617 (THE ACTIVE AGENT IN PLUVICTO, NOVARTIS), AS WELL AS 225AC-PSMA-617 ACROSS MULTIPLE PRECLINICAL PROSTATE CANCER MODELS.

ACTINIUM PHARMACEUTICALS PRESENTS NEW DATA DEMONSTRATING POTENT AND DURABLE EFFICACY OF ATNM-400, A FIRST-IN-CLASS MULTI-TUMOR ACTINIUM-225 RADIOTHERAPY, AT THE 32ND ANNUAL PROSTATE CANCER FOUNDATION SCIENTIFIC RETREAT

Actinium Pharmaceuticals, Inc.

ATNM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Actinium Pharmaceuticals, Inc.

ATNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATNM